已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis

医学 沙库比林、缬沙坦 缬沙坦 沙库比林 内科学 透析 肾脏疾病 心脏病学 血压
作者
Nguyễn Việt Dũng,Giang Thai Pham,Son Pham,Hoai Thi Thu Nguyen
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins]
卷期号:43 (4): 557-567 被引量:3
标识
DOI:10.1097/hjh.0000000000003972
摘要

The aim of this meta-analysis was to assess the efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease (ESKD) undergoing dialysis. We searched the Medline, Cochrane, Embase, Web of Science, and ClinicalTrials.gov databases for studies reporting outcomes after SV treatment. All analyses were performed utilizing the random effects models. Nineteen studies comprising 1597 patients with concomitant hypertension and ESKD undergoing dialysis were included. After sacubitril-valsartan treatment, significant reductions in both SBP and DBP were observed (mean change in SBP: -11.09 mmHg [95% confidence interval, 95% CI: -14.51,-7.66] and DBP: -4.37 mmHg [-6.36,-2.38]). Compared to conventional treatment, patients treated with sacubitril-valsartan had a lower risk of cardiovascular hospitalization (risk ratio: 0.63 [0.44,0.90]). Sacubitril-valsartan treatment showed a trend toward reducing the risk of all-cause mortality, although this was not statistically significant (risk ratio: 0.66 [0.27,1.60]). Evaluation of echocardiographic parameters among studies including hypertension patients with heart failure indicated that SV improved LVEF (mean change: +7.04%[+3.19, +10.90]), however this effect was more pronounced in the HFrEF patients ( Pinteraction =0.0003). Sacubitril-valsartan also reduced LVSd, LVDd, LAD, and E/e' ratio ( P < 0.05). The risks of severe hyperkalemia and symptomatic hypotension were comparable between sacubitril-valsartan treatment and conventional treatment ( P > 0.05). The present study revealed that sacubitril-valsartan treatment is well tolerated and could have potential benefits in hypertension patients with ESKD on dialysis by effectively controlling blood pressure, improving LVEF, reversing cardiac remodeling, and reducing the risk of cardiovascular hospitalization.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
01发布了新的文献求助10
1秒前
orixero的应助被Elaina采纳,获得10
1秒前
2秒前
传奇3的应助被fafafa采纳,获得10
2秒前
传奇3的应助被姜姜姜姜采纳,获得10
2秒前
我无语完成签到 ,获得积分10
3秒前
CATH完成签到 ,获得积分10
4秒前
4秒前
江河湖海完成签到,获得积分10
5秒前
453tfg发布了新的文献求助10
5秒前
宋宋发布了新的文献求助10
5秒前
kk完成签到 ,获得积分10
5秒前
6秒前
木木木木完成签到 ,获得积分10
6秒前
Cloud9527完成签到,获得积分10
8秒前
9秒前
刘一严完成签到 ,获得积分10
11秒前
11秒前
zhangyu哥发布了新的文献求助10
11秒前
今后的应助被01采纳,获得10
12秒前
伴青灯完成签到 ,获得积分10
13秒前
桐桐的应助被陆艳梅2023采纳,获得10
15秒前
星辰大海的应助被赖皮蛇采纳,获得10
16秒前
16秒前
小二郎的应助被li采纳,获得10
17秒前
英俊的谷蓝完成签到,获得积分10
18秒前
ss完成签到 ,获得积分10
18秒前
感动的夏岚完成签到,获得积分10
19秒前
huohuo2完成签到,获得积分10
20秒前
CipherSage的应助被苏翰英采纳,获得10
21秒前
悦兮完成签到 ,获得积分10
21秒前
土豪的糜发布了新的文献求助20
22秒前
huo完成签到,获得积分10
23秒前
23秒前
23秒前
24秒前
26秒前
hochorsin完成签到,获得积分10
27秒前
PizzaBob发布了新的文献求助10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172758
求助须知:如何正确求助?哪些是违规求助? 9565356
关于积分的说明 21779652
捐赠科研通 7764670
什么是DOI,文献DOI怎么找? 3431480
关于科研通互助平台的介绍 2555430
邀请新用户注册赠送积分活动 2476460